Hans-Georg Lerchen is Chief Scientist in the Medical Chemistry department in the R&D organization of Bayer AG, Pharmaceuticals Division. With a 31 years background in MedChem he is author or co-author of 80 patents or patent applications and 21 publications. His current research focus is drug delivery modalities, prodrugs and in particular antibody drug conjugates.
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policy makers.